U.S. Markets close in 32 mins

Completion of Manufacturing of Clinical Grade FasL Enables Cellect to Expedite U.S. Clinical Programs into Multiple Studies

Supports Collaborations with Cell and Gene Therapy Companies

TEL AVIV, Israel, January 28, 2019 /PRNewswire/ --

Cellect Biotechnology Ltd. (APOP), a developer of a novel stem cell production technology, today announced it has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier. Based on its process and the results of the ongoing clinical trial, the Company has scaled up manufacturing of FasL for hundreds of personal batches fully scalable to hundreds of thousands of batches for clinical and collaborative purposes. The Company expects to form an alliance of clinical and commercial cell therapy centers using the ApoGraft™ technology.

The FasL protein is central to Cellect's technology of cell separation and functional selection of stem cells and is the key active ingredient in Cellect's ApoGraft™ and Apotainer product lines. Cellect's FasL based technology is intended to enable achieving stem cells for any indication in quality, quantity and at a competitive price; and is expected to improve the safety and efficacy of stem cell therapies and regenerative medicine.

Dr. Shai Yarkoni, Cellect CEO comments: "the proven scalability of our clinical grade production of FasL is a major step forward and opens the door for multiple global clinical activities and collaborations, as well as supporting our existing and planned global partners. This is an important milestone to becoming the standard enabling technology for the enrichment of stem cells and manufacturing of any adult stem cell-based products for companies developing stem cell therapies and for researchers and academia engaged in adult stem cell research. We are committed to enabling a multi-billion global market over the next five years while positioning Cellect towards potentially meeting commercial demand for millions of patients worldwide in need of stem cell therapy, as well as providing raw materials for stem cell research centers and the biobanking industry."

About Regenerative Medicine and Cell Therapy 

Regenerative medicine is a novel approach using cells and tissues to replace or regenerate human cells, tissues or organs in a wide variety of medical indications. This could be achieved by either stimulating the body to use its own repair mechanisms to heal tissues or organs, or by growing tissues and organs in the laboratory and transplanting them into the patient.

Stem cells play a major role in the achievement of the extraordinary potential results in regenerative medicine. In cell therapies they can be injected to reconstitute the entire blood system in bone marrow transplantations. Alternatively, their injection can supply the necessary biologically active molecules to induce the patients' own cells to regain normal function, as used in immunomodulation therapy. In tissue engineering, where entire organs like the retina, bone, cartilage or the skin may be replaced, stem cells are the starting material for the growth of such tissues in the laboratory. Moreover, in tissue engineering an artificial system might be created by inducing cells to perform certain biochemical functions lost due to disease (e.g., artificial pancreas or liver).

Regenerative medicine using cellular therapy in combination with new technologies like tissue engineering and gene transfer can be used in a virtually unlimited number of indications. The most frequently used cells are hematopoietic stem cells (HSC) due to their capability to reproduce the entire blood system in blood cancer and hematological disorders. Mesenchymal stem cells, which have the capability to differentiate to a large number of tissue types like bone, cartilage, fat, heart muscle and more, are of growing importance. Potential applications of cell therapies include treating cancers, autoimmune disease, urinary problems and infectious disease, rebuilding damaged cartilage in joints, repairing spinal cord injuries, improving a weakened immune system, and helping patients with neurological disorders.

About Cellect Biotechnology Ltd.  

Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue to any application of those cells. The technology aims to improve a variety of cell-based therapies.

The Company's technology is expected to provide research institutes, hospitals and pharma companies with the tools to rapidly produce stem cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's ongoing clinical trial is treating patients undergoing bone marrow transplantations in cancer treatment.

Forward Looking Statements 

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's intent regarding future production capability. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC.

Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer
www.cellect.co
+972-9-974-1444

EVC Group LLC
Michael Polyviou / Todd Kehrli
(732)933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com


  • Interested In Ørsted A/S (CPH:ORSTED)? Here's What Its Recent Performance Looks Like
    Business
    Simply Wall St.

    Interested In Ørsted A/S (CPH:ORSTED)? Here's What Its Recent Performance Looks Like

    When Ørsted A/S (CPH:ORSTED) released its most recent earnings update (31 December 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. Understanding how Ørsted performed requires a benchmark rather than trying to assess a standalone number at one point in time. Below is a quick commentary on how I see ORSTED has performed.

  • Here's Why StoneCo Stock Is Plunging Today
    Business
    Motley Fool

    Here's Why StoneCo Stock Is Plunging Today

    Shares of Brazilian fintech company StoneCo (NASDAQ: STNE), which gained notoriety in recent months after being added to Berkshire Hathaway's portfolio, are plummeting today. Generally speaking, moves like this are often seen after earnings announcements, but StoneCo isn't set to report earnings again for another couple months. In this case, the plunge appears to be triggered by a move from a rival company.

  • This is how bad the health-care stock selloff looks on charts—Is that a good thing?
    Business
    MarketWatch

    This is how bad the health-care stock selloff looks on charts—Is that a good thing?

    If there are any investors still wondering how vicious the selloff in health care stocks has been over the past couple of weeks, the charts below are worth 1,000 words. The SPDR Health Care Select Sector exchange-traded fund (XLV) fell 0.1% in afternoon trade Thursday, reversing earlier gains of as much as 0.8%, to put it on track to close at a 3 1/2-month low. The ETF (XLV) has lost 0.9% year to date, making it the only SPDR ETF tracking the S&P 500's 11 sectors to be down this year, amid increased political rhetoric regarding “Medicare for All” plans and lower drug prices.

  • A Close Look At Fastenal Company's (NASDAQ:FAST) 33% ROCE
    Business
    Simply Wall St.

    A Close Look At Fastenal Company's (NASDAQ:FAST) 33% ROCE

    Today we'll look at Fastenal Company (NASDAQ:FAST) and reflect on its potential as an investment. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. First, we'll go over how we calculate ROCE.

  • Boeing 'shielded' from 737 Max order cancellations
    Business
    MarketWatch

    Boeing 'shielded' from 737 Max order cancellations

    Don't expect Boeing Co. to face a slew of order cancellations following the 737 Max debacle. Airlines, Boeing's (BA) main customers, are hungry for fuel-efficient single-aisle aircraft such as the Max, and there's a long backlog for the jet's closest competitor, Airbus SE' (FR:AIR) A320neo, analysts at Oxford Economics said in a note Thursday. “That will shield Boeing from a mass cancellation of orders,” the analysts said.

  • Why the Zoom and Pinterest IPOs matter so much for valuations
    Business
    Yahoo Finance Video

    Why the Zoom and Pinterest IPOs matter so much for valuations

    Zoom and Pinterest both began trading on the public market today. Yahoo Finance's Zack Guzman and Kristin Myers are joined by Lauren Smith Brody, 'The Fifth Trimester' author and founder, and Barrett Daniels, Deloitte & Touche National IPO Services Leader, to discuss why both IPOs matter so much for valuations.

  • Is There An Opportunity With AxoGen, Inc.'s (NASDAQ:AXGN) 48% Undervaluation?
    Business
    Simply Wall St.

    Is There An Opportunity With AxoGen, Inc.'s (NASDAQ:AXGN) 48% Undervaluation?

    Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. This is done using the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

  • Is Aphria a Buy on the Dip?
    Business
    Motley Fool

    Is Aphria a Buy on the Dip?

    Shares of Aphria (NYSE: APHA) have tumbled about 16% since the company reported earnings results for its fiscal third quarter. This was the first full quarter since the company and its peers began selling adult-use recreational marijuana in Canada, and investors enthusiastic about the future are wondering if the market has overreacted and created a bargain opportunity. Let's take a closer look at the road ahead of Aphria to see if this troubled marijuana stock is a buy right now.

  • Is Zynga Poised for Significant Growth in 2019 and Beyond?
    Business
    Market Realist

    Is Zynga Poised for Significant Growth in 2019 and Beyond?

    These Tech Stocks Could Be Overvalued at Their Current Prices(Continued from Prior Part)ZNGA's returns The stock of gaming company Zynga (ZNGA) has generated a return of 51% in the last 12 months. Since the start of 2019, the stock is up 36%.

  • How Much Of Vodafone Group Plc (LON:VOD) Do Institutions Own?
    Business
    Simply Wall St.

    How Much Of Vodafone Group Plc (LON:VOD) Do Institutions Own?

    Every investor in Vodafone Group Plc (LON:VOD) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Vodafone Group is a pretty big company.

  • Have Insiders Been Selling Texas Pacific Land Trust (NYSE:TPL) Shares This Year?
    Business
    Simply Wall St.

    Have Insiders Been Selling Texas Pacific Land Trust (NYSE:TPL) Shares This Year?

    So we'll take a look at whether insiders have been buying or selling shares in Texas Pacific Land Trust (NYSE:TPL). Do Insider Transactions Matter? Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market.

  • Harry Boxer: Two marijuana stocks are among charts worth watching
    Business
    MarketWatch

    Harry Boxer: Two marijuana stocks are among charts worth watching

    Marijuana stocks are among our top charts to watch today. Bank of America Merrill Lynch named the company as one of three marijuana stocks to buy. The stock, after sharp year-to-date gains, has been consolidating in recent weeks, but may be on the verge of its next leg up with cannabis stocks in general.

  • California Water Service Group (CWT) Reports Next Week: Wall Street Expects Earnings Growth
    Business
    Zacks

    California Water Service Group (CWT) Reports Next Week: Wall Street Expects Earnings Growth

    Wall Street expects a year-over-year increase in earnings on higher revenues when California Water Service Group (CWT) reports results for the quarter ended March 2019. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 25. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

  • Nasdaq President says watch out for these IPOs in 2019
    Business
    Yahoo Finance Video

    Nasdaq President says watch out for these IPOs in 2019

    Nasdaq President Nelson Griggs joins Yahoo Finance's Julie Hyman and Adam Shapiro to talk about the 2019 IPO rush and what we can expect for the rest of the year.

  • Business
    Barrons.com

    GE Stock Got a Thumbs Up From a Mysterious 'Smartest Man'

    GE)'s beaten-down stock is up 25% year to date, and Melius Research analyst Scott Davis says the smartest industrial investor he knows is buying the shares. That's a tantalizing statement. Who is this investing star?

  • Why Check Point Software Stock Dropped 8% Today
    Business
    Motley Fool

    Why Check Point Software Stock Dropped 8% Today

    Shares of IT security specialist Check Point Software Technologies (NASDAQ: CHKP) plunged more than 11% in early trading on the Nasdaq today before retracing to about an 8.2% loss as of 12:40 p.m. EDT. Check Point reported its fiscal first-quarter 2019 earnings this morning, but earnings weren't the problem this time -- guidance was. An earnings beat could have sent Check Point stock up today.

  • Why Nintendo Stock Popped Today
    News
    Motley Fool

    Why Nintendo Stock Popped Today

    What happened Shares of Nintendo (NASDAQOTH: NTDOY) were up 13.6% as of 1:30 p.m. EDT Thursday after news emerged that the company's Switch gaming console will soon begin selling in China. But Nintendo won't be selling the devices directly.

  • Why Mustang Bio Stock Is On Fire Today
    News
    Motley Fool

    Why Mustang Bio Stock Is On Fire Today

    Mustang's shares are blasting off in response to the news that an experimental gene therapy, MB-107, for "bubble boy" disease -- also known as X-linked severe combined immunodeficiency, or XSCID for short -- reportedly cured eight boys with the deadly condition. Equally critical, Mustang said that the boys are showing no signs of unintended side effects from the therapy -- an issue that has derailed prior gene therapies for XSCID. Mustang licensed MB-107 from St. Jude Children's Research Hospital.

  • Pier 1 liquidation is a possibility, analysts say
    Business
    MarketWatch

    Pier 1 liquidation is a possibility, analysts say

    Pier 1 Imports Inc.'s Interim Chief Executive Cheryl Bachelder may have taken an optimistic tone after the home décor retailer reported disappointing fourth-quarter earnings, but analysts were bearish, bringing up the possibility of a liquidation in the not-so-distant future. “Given the trends in business, and its negative earnings per share, EBITDA [earnings before interest, tax, depreciation and amortization], and free cash flow, we see Pier 1 and its $1.6 billion in revenues as potentially at risk of needing liquidation if trends don't improve,” wrote KeyBanc Capital Markets analysts led by Bradley Thomas. KeyBanc thinks Kirkland's Inc. (KIRK)  , Williams-Sonoma Inc. (WSM)  , Bed Bath & Beyond Inc. (BBBY)  and At Home Group Inc. (HOME)  would benefit from a Pier 1 (PIR)  liquidation.

  • Why Tandem Diabetes Care Stock Sank Today
    Business
    Motley Fool

    Why Tandem Diabetes Care Stock Sank Today

    What happened Shares of Tandem Diabetes Care (NASDAQ: TNDM) closed down 9.9% on Wednesday after sinking as much as 11.9% earlier in the day. There wasn't any negative news specific to the insulin pump maker. However, healthcare stocks overall took a beating on Wednesday amid increasing concerns about the political climate in Washington D.C., particularly with the Medicare for All plan proposed by presidential candidate Sen. Bernie Sanders (I-VT).

  • Here's Why Blackstone Shares Jumped on Thursday
    Business
    Motley Fool

    Here's Why Blackstone Shares Jumped on Thursday

    Shares of Blackstone Group (NYSE: BX) climbed nearly 7% on Thursday morning after the alternative asset manager reported first-quarter earnings that blew past expectations and announced plans to convert to a corporation from a partnership. Blackstone, before markets opened, said it had earned $0.71 per share in the first quarter, easily surpassing the consensus estimate for $0.53 per share in earnings. The partnership structure has prevented some classes of investors, namely pension funds and other tax-exempt institutions, from buying shares of Blackstone, and has made the company ineligible for inclusion on certain indexes.

  • Why Century Aluminum Stock Dropped Today
    Business
    Motley Fool

    Why Century Aluminum Stock Dropped Today

    But here's the thing: While this is "earnings season," a time of year we've been trained to expect to see big rises (and falls) in our stocks, Century Aluminum hasn't reported earnings yet. In fact, it's not expected to report earnings until April 30. Unfortunately, while Century hasn't yet reported, Alcoa (NYSE: AA) just did -- and it seems that Alcoa's bad news is turning out to be even worse news for Century.

  • Imagine Owning New Media Investment Group (NYSE:NEWM) And Wondering If The 37% Share Price Slide Is Justified
    Business
    Simply Wall St.

    Imagine Owning New Media Investment Group (NYSE:NEWM) And Wondering If The 37% Share Price Slide Is Justified

    By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. New Media Investment Group managed to increase earnings per share from a loss to a profit, over the last 12 months. Earnings per share growth rates aren't particularly useful for comparing with the share price, when a company has moved from loss to profit.

  • Canopy Growth's Acreage Acquisition Boosts Sentiment
    Business
    Market Realist

    Canopy Growth's Acreage Acquisition Boosts Sentiment

    Canopy Growth's Acreage Acquisition Boosts SentimentThe gains The cannabis sector appeared to show optimism after Canopy Growth (WEED)(CGC) announced that it would acquire Acreage Holdings (ACRGF), a US multi-state cannabis operator with

  • Kinder Morgan Delivers Solid First-Quarter Performance
    Business
    Motley Fool

    Kinder Morgan Delivers Solid First-Quarter Performance

    Kinder Morgan's (NYSE: KMI) first-quarter results came in about as expected. The solid start to 2019 has the company on pace to hit its full-year budget for cash flow. It also allowed Kinder Morgan to fulfill its promise to boost the dividend by 25%.